4.7 Review

ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis

期刊

BRITISH JOURNAL OF PHARMACOLOGY
卷 169, 期 3, 页码 477-492

出版社

WILEY
DOI: 10.1111/bph.12159

关键词

angiotensin-(1-7); Mas receptor; inflammation; fibrosis; renal diseases

资金

  1. CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil)
  2. CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazil)
  3. FAPEMIG (Fundacao de Amparo a Pesquisa do Estado de Minas Gerais, Brazil)
  4. European Community [HEALTH-F4-2011-281608]

向作者/读者索取更多资源

Recent advances have improved our understanding of the renin-angiotensin system (RAS). These have included the recognition that angiotensin (Ang)-(1-7) is a biologically active product of the RAS cascade. The identification of the ACE homologue ACE2, which forms Ang-(1-7) from Ang II, and the GPCR Mas as an Ang-(1-7) receptor have provided the necessary biochemical and molecular background and tools to study the biological significance of Ang-(1-7). Most available evidence supports a counter-regulatory role for Ang-(1-7) by opposing many actions of Ang II on AT1 receptors, especially vasoconstriction and proliferation. Many studies have now shown that Ang-(1-7) by acting via Mas receptor exerts inhibitory effects on inflammation and on vascular and cellular growth mechanisms. Ang-(1-7) has also been shown to reduce key signalling pathways and molecules thought to be relevant for fibrogenesis. Here, we review recent findings related to the function of the ACE2/Ang-(1-7)/Mas axis and focus on the role of this axis in modifying processes associated with acute and chronic inflammation, including leukocyte influx, fibrogenesis and proliferation of certain cell types. More attention will be given to the involvement of the ACE2/Ang-(1-7)/Mas axis in the context of renal disease because of the known relevance of the RAS for the function of this organ and for the regulation of kidney inflammation and fibrosis. Taken together, this knowledge may help in paving the way for the development of novel treatments for chronic inflammatory and renal diseases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据